Objective： To comparatively study the expressive conditions of platelet activation related factors （GPⅠb, GPⅡb-Ⅲa and GMP-140） in healthy subjects and patients with coronary heart disease （CHD） of blood-stasis...Objective： To comparatively study the expressive conditions of platelet activation related factors （GPⅠb, GPⅡb-Ⅲa and GMP-140） in healthy subjects and patients with coronary heart disease （CHD） of blood-stasis （BS） or non-blood-stasis （non-BS） syndrome, and to analyze the relationship between the activities of various glycoproteins and the polymorphism of genes. Methods： With case control design adopted, patients with the CHD （40 of BS, 37 of non-BS） and 39 healthy subjects for control, all fitting to the inclusion criteria, were selected in this study. The number of affected coronary branches was recorded by the contrast examination. The mean fluorescence intensity （MFI） of GPⅠb, GPⅡb-Ⅲa, and GMP-140 （CD42b, CD61, CD62p） in patients and healthy persons was measured with flow cytometry, the polymorphism of HPA-3 gene was detected by Taqman probe technique and that of HPA-2 gene was determined by gene sequencing. Results： MFI of CD61 and CD62p was higher in the CHD patients than in the healthy control, which was also higher in patients of BS syndrome than in patients of non-BS syndrome （P〈0.05）; MFI of CD42b was lower in the CHD patients than in the healthy control （P〈0.05）, but showing insignificant difference between BS and non-BS syndrome （P〉0.05）; at the same time, no significant difference of all the above-mentioned three MFI could be found in patients with various numbers of affected coronary branches, neither in patients with different genotypes at GPⅡb HPA-3 and GPⅠb HPA-2 polymorphism loci （P〉0.05）. Conclusion： （1） The activities of GP Ⅱ b-Ⅲa and GMP-140 were obviously increased in the genesis and developing process of CHD and CHD of BS syndrome, and so they could be taken as one of the objective indexes for microscopic diagnosis of BS syndrome. （2） The level of GPⅠb was lower in CHD patients than in healthy persons, but it was not a sensitive indicator for BS syndrome of CHD. （3） Levels of GP Ⅱb-Ⅲa, GPⅠb and GMP-140 were not related with the number of affected coronary branches in CHD patients. （4） The changes in amino-acids expression induced by the two loci brought no significant influence on GPⅠb and GP Ⅱb-Ⅲa activities.展开更多
目的探讨抗凝血酶III(AT-III)、凝血因子Ⅴ(FactorV)基因多态性与广东籍汉族早孕期妇女子痫前期和子痫发生的关系。方法回顾性分析567例早孕期广东籍汉族妇女AT-III及FactorV基因的突变情况,将其中54例妊娠20周后发生子痫前期和子痫的...目的探讨抗凝血酶III(AT-III)、凝血因子Ⅴ(FactorV)基因多态性与广东籍汉族早孕期妇女子痫前期和子痫发生的关系。方法回顾性分析567例早孕期广东籍汉族妇女AT-III及FactorV基因的突变情况,将其中54例妊娠20周后发生子痫前期和子痫的患者作为观察组,513例正常妊娠者作为对照组。基因突变检测分别采用DdeI和MnlI限制性内切酶片段长度多态性分析。结果观察组ATIIIDdeI++、DdeI+-及DdeI--基因型频率分别为51.9%、27.8%和20.4%,对照组则分别为66.7%、25.5%和7.8%。观察组AT III DdeI-基因型频率显著高于对照组(34.3%,20.6%,P<0.01),AT III DdeI--基因型在子痫前期和子痫发病中的相对风险率为3.025。观察组和对照组均未检出Factor VLeiden突变。结论 ATIII基因多态性可能与广东籍汉族妇女子痫前期和子痫发病相关,而Factor VLeiden突变与其发病无关。展开更多
基金Supported by the Major Program Project of National Natural Science Foundation of China(No.90409021)
文摘Objective： To comparatively study the expressive conditions of platelet activation related factors （GPⅠb, GPⅡb-Ⅲa and GMP-140） in healthy subjects and patients with coronary heart disease （CHD） of blood-stasis （BS） or non-blood-stasis （non-BS） syndrome, and to analyze the relationship between the activities of various glycoproteins and the polymorphism of genes. Methods： With case control design adopted, patients with the CHD （40 of BS, 37 of non-BS） and 39 healthy subjects for control, all fitting to the inclusion criteria, were selected in this study. The number of affected coronary branches was recorded by the contrast examination. The mean fluorescence intensity （MFI） of GPⅠb, GPⅡb-Ⅲa, and GMP-140 （CD42b, CD61, CD62p） in patients and healthy persons was measured with flow cytometry, the polymorphism of HPA-3 gene was detected by Taqman probe technique and that of HPA-2 gene was determined by gene sequencing. Results： MFI of CD61 and CD62p was higher in the CHD patients than in the healthy control, which was also higher in patients of BS syndrome than in patients of non-BS syndrome （P〈0.05）; MFI of CD42b was lower in the CHD patients than in the healthy control （P〈0.05）, but showing insignificant difference between BS and non-BS syndrome （P〉0.05）; at the same time, no significant difference of all the above-mentioned three MFI could be found in patients with various numbers of affected coronary branches, neither in patients with different genotypes at GPⅡb HPA-3 and GPⅠb HPA-2 polymorphism loci （P〉0.05）. Conclusion： （1） The activities of GP Ⅱ b-Ⅲa and GMP-140 were obviously increased in the genesis and developing process of CHD and CHD of BS syndrome, and so they could be taken as one of the objective indexes for microscopic diagnosis of BS syndrome. （2） The level of GPⅠb was lower in CHD patients than in healthy persons, but it was not a sensitive indicator for BS syndrome of CHD. （3） Levels of GP Ⅱb-Ⅲa, GPⅠb and GMP-140 were not related with the number of affected coronary branches in CHD patients. （4） The changes in amino-acids expression induced by the two loci brought no significant influence on GPⅠb and GP Ⅱb-Ⅲa activities.
文摘目的探讨抗凝血酶III(AT-III)、凝血因子Ⅴ(FactorV)基因多态性与广东籍汉族早孕期妇女子痫前期和子痫发生的关系。方法回顾性分析567例早孕期广东籍汉族妇女AT-III及FactorV基因的突变情况,将其中54例妊娠20周后发生子痫前期和子痫的患者作为观察组,513例正常妊娠者作为对照组。基因突变检测分别采用DdeI和MnlI限制性内切酶片段长度多态性分析。结果观察组ATIIIDdeI++、DdeI+-及DdeI--基因型频率分别为51.9%、27.8%和20.4%,对照组则分别为66.7%、25.5%和7.8%。观察组AT III DdeI-基因型频率显著高于对照组(34.3%,20.6%,P<0.01),AT III DdeI--基因型在子痫前期和子痫发病中的相对风险率为3.025。观察组和对照组均未检出Factor VLeiden突变。结论 ATIII基因多态性可能与广东籍汉族妇女子痫前期和子痫发病相关,而Factor VLeiden突变与其发病无关。
